Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

Danish Memon, Hira Rizvi, George Fromm, Jayon Lihm, Adam J. Schoenfeld, Jennifer L. Sauter, Jia Luo, Andrew Chow, Umesh Bhanot, Caroline G. McCarthy, Darwin Ye, Chad Vanderbilt, Cailian Liu, Mohsen Abu-Akeel, Andrew J. Plodkowski, Nicholas McGranahan, Marta Łuksza, Benjamin D. Greenbaum, Taha Merghoub, Andy J. Minn, Pedro Beltrão, Taylor H. Schreiber, Martin L. Miller, Matthew D. HellmannbioRxiv 2021 · DOI

Abstract

Although cancer immunotherapy with PD-(L)1 blockade is now routine treatment for patients with lung cancer, remarkably little is known about acquired resistance. We examined 1,201 patients with NSCLC treated with PD-(L)1 blockade to clinically characterize acquired resistance, finding it to be common (occurring in more than 60% of initial responders), with persistent but diminishing risk over time, and with distinct metastatic and survival patterns compared to primary resistance. To examine the molecular phenotype and potential mechanisms of acquired resistance, we performed whole transcriptome and exome tumor profiling in a subset of NSCLC patients (n=29) with acquired resistance. Systematic immunogenomic analysis revealed that tumors with acquired resistance generally had enriched signals of inflammation (including IFNγ signaling and inferred CD8+ T cells) and could be separated into IFNγ upregulated and stable subsets. IFNγ upregulated tumors had putative routes of resistance with signatures of dysfunctional interferon signaling and mutations in antigen presentation genes. Transcriptomic profiling of cancer cells from a murine model of acquired resistance to PD-(L)1 blockade also showed evidence of dysfunctional interferon signaling and acquired insensitivity to in vitro interferon gamma treatment. In summary, we characterized clinical and molecular features of acquired resistance to PD-(L)1 blockade in NSCLC and found evidence of ongoing but dysfunctional IFN response. The persistently inflamed, rather than excluded or deserted, tumor microenvironment of acquired resistance informs therapeutic strategies to effectively reprogram and reverse acquired resistance.

Introduction

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have revolutionized the treatment of non-small cell lung cancer (NSCLC). Despite these advances, many patients who initially benefit from therapy eventually experience disease progression. This phenomenon, known as acquired resistance (AR), remains a significant clinical challenge. While the mechanisms underlying primary resistance (lack of initial response) have been extensively studied, the clinical and molecular characteristics of AR have been less clear. This study aims to define the clinical landscape of AR in a large patient cohort and investigate the molecular drivers of relapse using paired longitudinal tumor samples.

Methods

Researchers conducted a comprehensive analysis using a multi-faceted approach:

  1. Clinical Cohort Study: A cohort of 1,201 patients with NSCLC treated with PD-(L)1 blockade at Memorial Sloan Kettering Cancer Center was evaluated to characterize the timing, metastatic patterns, and survival outcomes associated with acquired resistance.
  2. Molecular and Genomic Profiling: In a subset of 29 patients, whole-exome sequencing (WES) and transcriptomic (RNA-seq) analysis were performed on paired tumor samples collected before treatment and at the time of resistance.
  3. Preclinical Validation: A murine CT26 tumor model was utilized to generate a lineage with acquired resistance to PD-1 blockade, facilitating transcriptomic comparison with sensitive parental lines.

Results

Clinical Landscape of Acquired Resistance

Acquired resistance is a frequent outcome for initial responders, with a cumulative incidence of 61% at five years. The risk of progression is highest in the first two years but persists long-term. Clinically, AR is distinct from primary resistance in several key ways. Patients with AR exhibit different metastatic patterns; for example, liver metastases are significantly less common at the time of acquired resistance (7%) compared to primary resistance (31%).

Crucially, patients who develop acquired resistance have a significantly better prognosis following disease progression. The median post-progression survival for AR patients was 18.9 months, compared to just 4.4 months for those with primary resistance, suggesting that the immune system may maintain partial control over the tumor even after clinical relapse.

Clinical characterization of acquired resistance in NSCLC, detailing cumulative incidence (A), time to resistance (B), relative risk (C), baseline features (D), common sites of progression (E), and post-progression survival (F).

Molecular Drivers: The IFNγ Paradox

Molecular profiling revealed that AR tumors are typically not "immune deserts." Instead, they often show increased levels of inflammation, including higher CD8+ T cell infiltration and IFNγ signaling compared to their pre-treatment state. This "inflamed" but resistant state is characterized by dysfunctional interferon signaling.

The study identified two distinct molecular subsets: "IFNγ upregulated" and "IFNγ stable." In the upregulated group, chronic exposure to IFNγ appeared to drive a state of dysfunctional inflammation and T-cell exhaustion. Furthermore, the immune system appears to exert selective pressure on the tumor, leading to the acquisition of mutations in antigen presentation genes (e.g., B2M) or the loss of HLA expression in 75% of patients with significant clonal remodeling. These "stealth" mutations allow tumors to evade immune recognition despite an active inflammatory environment.

Discussion

Acquired resistance to immunotherapy in NSCLC is characterized by a persistently inflamed but dysfunctional tumor microenvironment. Unlike primary resistance, AR is associated with unique metastatic patterns and a more favorable post-progression survival profile. The discovery that these tumors are often "hot" rather than "cold" suggests that therapeutic strategies should focus on reversing interferon dysfunction and restoring antigen presentation rather than simply increasing immune infiltration. These insights provide a roadmap for developing next-generation therapies to overcome resistance and extend the benefit of immunotherapy for lung cancer patients.

Summary updated

Abstract

Abstract Although cancer immunotherapy with PD-(L)1 blockade is now routine treatment for patients with lung cancer, remarkably little is known about acquired resistance. We examined 1,201 patients with NSCLC treated with PD-(L)1 blockade to clinically characterize acquired resistance, finding it to be common (occurring in more than 60% of initial responders), with persistent but diminishing risk over time, and with distinct metastatic and survival patterns compared to primary resistance. To examine the molecular phenotype and potential mechanisms of acquired resistance, we performed whole transcriptome and exome tumor profiling in a subset of NSCLC patients (n=29) with acquired resistance. Systematic immunogenomic analysis revealed that tumors with acquired resistance generally had enriched signals of inflammation (including IFNγ signaling and inferred CD8+ T cells) and could be separated into IFNγ upregulated and stable subsets. IFNγ upregulated tumors had putative routes of resistance with signatures of dysfunctional interferon signaling and mutations in antigen presentation genes. Transcriptomic profiling of cancer cells from a murine model of acquired resistance to PD-(L)1 blockade also showed evidence of dysfunctional interferon signaling and acquired insensitivity to in vitro interferon gamma treatment. In summary, we characterized clinical and molecular features of acquired resistance to PD-(L)1 blockade in NSCLC and found evidence of ongoing but dysfunctional IFN response. The persistently inflamed, rather than excluded or deserted, tumor microenvironment of acquired resistance informs therapeutic strategies to effectively reprogram and reverse acquired resistance.
BibTeX
@misc{memon2021clinical,
  author = {Danish Memon and Hira Rizvi and George Fromm and Jayon Lihm and Adam J. Schoenfeld and Jennifer L. Sauter and Jia Luo and Andrew Chow and Umesh Bhanot and Caroline G. McCarthy and Darwin Ye and Chad Vanderbilt and Cailian Liu and Mohsen Abu-Akeel and Andrew J. Plodkowski and Nicholas McGranahan and Marta Łuksza and Benjamin D. Greenbaum and Taha Merghoub and Andy J. Minn and Pedro Beltrão and Taylor H. Schreiber and Martin L. Miller and Matthew D. Hellmann},
  title = {{Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer}},
  year = {2021},
  doi = {10.1101/2021.07.21.452854},
  howpublished = {bioRxiv},
}
Figure